Activation of the mTOR signalling pathway is required for pancreatic growth in protease-inhibitor-fed mice by Crozier, Stephen J. et al.
J Physiol 573.3 (2006) pp 775–786 775
Activation of the mTOR signalling pathway is required
for pancreatic growth in protease-inhibitor-fed mice
Stephen J. Crozier, M. Dolors Sans, LiLi Guo, Louis G. D’Alecy and John A. Williams
Department of Molecular and Integrative Physiology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
Cholecystokinin (CCK)-induced pancreatic growth in mice involves parallel increases in DNA
and protein. The mammalian target of rapamycin (mTOR) signalling pathway regulates mRNA
translation and its activation is implicated in growth of various tissues. The aim of this study
was to elucidate whether mTOR activation is required for pancreatic growth in a mouse model
of increased endogenous CCK release. In mice fed chow containing the synthetic protease
inhibitor camostat, protein synthetic rates and phosphorylation of two downstream targets
of mTOR, eukaryotic initiation factor 4E binding protein 1 (4E-BP1) and the ribosomal protein
S6 (S6), increased in comparison with fasted controls. The camostat-induced increases in protein
synthesis and 4E-BP1 and S6 phosphorylation were almost totally abolished by administration
of the mTOR inhibitor rapamycin 1 h prior to camostat feeding. In contrast, the phosphorylation
of ERK1/2 and JNK and the expression of the early response genes c-jun, c-fos, ATF3 and egr-1
induced by camostat feeding were not affected by rapamycin. In mice fed camostat for 7 days,
the ratio of pancreatic to body weight increased by 143%, but when rapamycin was administered
daily this was reduced to a 22% increase. Changes in pancreatic mass were paralleled by protein
and DNA content following camostat feeding and rapamycin administration. Moreover, while
BrdU incorporation, an indicator of DNA synthesis, was increased to 448% of control values
after 2 days of camostat feeding, rapamycin administration completely inhibited this increase.
We conclude that the mTOR signalling pathway is required for CCK-induced cell division and
pancreatic growth.
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Under physiological conditions in the adult, there is a
low rate of cellular turnover and little change in the size
of the pancreas. However, growth of the adult pancreas
is possible in response to hyperphagia and/or increased
dietary protein intake and in response to tissue injury,
such as following pancreatitis (Pearson et al. 1977; Green
et al. 1986; Sato et al. 2003). Gastrointestinal hormones can
regulate cell-cycle progression and cellular hypertrophy in
exocrine (acinar) cells of the pancreas. In particular, the
hormone cholecystokinin (CCK) has been implicated in
stimulating acinar cell growth (Logsdon, 1999). Feeding an
oral trypsin inhibitor is associated with pancreatic growth
(Chernick et al. 1948; Melmed & Bouchier, 1968; Goke
et al. 1986; Tashiro et al. 2004) concomitant with increased
concentrations of intestinal and circulating CCK (Melmed
& Bouchier, 1968; Melmed et al. 1976; McGuinness
et al. 1984; Goke et al. 1986), and exogenous CCK
administration stimulates pancreatic growth in rodents
(Dembinski & Johnson, 1980; Niederau et al. 1987) and
cell division in acinar cell cultures (Logsdon, 1986).
Furthermore, oral trypsin inhibitor-induced pancreatic
growth is abated by coadministration of CCK antagonists
(Wisner et al. 1988) and is absent in CCK (Tashiro et al.
2004) and CCK-A receptor-deficient mice (Sato et al. 2002,
2003).
The protein phosphatase calcineurin, and several
protein kinases, including ERKs, JNKs and the mammalian
target of rapamycin (mTOR), are activated in the
pancreases of mice fed the synthetic trypsin inhibitor
camostat (Sans & Williams, 2004; Tashiro et al. 2004,
2006). Administration of calcineurin inhibitors to these
mice prevents pancreatic growth (Tashiro et al. 2004).
Thus, the calcineurin signal transduction pathway appears
to be necessary for CCK-induced pancreatic growth.
However, the role of the aforementioned protein kinases
in pancreatic growth has yet to be elucidated.
mTOR is an atypical protein kinase that integrates
nutritional and mitogenic signals to control cell growth via
phosphorylation of its downstream effectors (Avruch et al.
2005; Martin & Hall, 2005). Two of the most well-studied
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effectors of mTOR, the eukaryotic initiation factor
(eIF)4E binding protein 1 (4E-BP1) and the ribosomal
protein S6 kinase 1 (S6K1) are important regulators of
protein synthesis (Shah et al. 2000). Protein synthesis
is regulated primarily at the stage of mRNA translation
initiation wherein an initiator-methionyl tRNA and
mRNA are delivered to the ribosome (Merrick, 1992).
A protein complex consisting of the initiation factors
eIF4A, eIF4G and eIF4E facilitates delivery of mRNA
to the ribosome. 4E-BP1 limits the formation of
this complex through sequestration of eIF4E; however,
increased phosphorylation of 4E-BP1 diminishes its
binding capacity and leads to increased rates of translation
initiation and protein synthesis (Graves et al. 1995). When
S6K1 is highly phosphorylated its kinase activity towards
the ribosomal protein S6 (S6) and eIF4B is increased
(Dufner & Thomas, 1999; Holz et al. 2005). Although
the mechanism remains poorly defined, phosphorylation
of S6 and eIF4B results in enhanced translation of
a subset of mRNAs that encode components of the
translational apparatus (Meyuhas, 2000; Khan & Goss,
2005). Therefore, increased phosphorylation of S6K1 and
its downstream targets is associated with an increased
capacity for protein synthesis.
CCK stimulates global pancreatic protein synthetic
rates in vitro and in vivo (Korc et al. 1981; Rausch
et al. 1986; Williams, 2001; Sans et al. 2002). CCK
stimulates the PI3K signalling pathway (Bi & Williams,
2004) and studies utilizing the PI3K inhibitor wortmannin
have demonstrated that CCK-induced stimulation of
protein synthesis requires activation of the mTOR
pathway in a PI3K-dependent manner (Bragado et al.
1998; Sans & Williams, 2002). Moreover, CCK-induced
stimulation of protein synthesis in vitro is associated
with increased phosphorylation of 4E-BP1 and S6, and
the highly specific mTOR antagonist rapamycin inhibits
these phosphorylation changes and the increase in protein
synthesis rates (Bragado et al. 1998). It is currently
not known whether activation of the mTOR pathway is
required for pancreatic growth in vivo. Therefore, the
objective of this study was to elucidate whether inhibition
of the mTOR signalling pathway prevents pancreatic




Ono Pharmaceutical Company (Osaka, Japan) generously
provided camostat (FOY-305). Rapamycin was obtained
from LC Laboratories (Woburn, MA, USA), low viscosity
carboxymethyl cellulose (CMC) was from Sigma-Aldrich
(St Louis, MO, USA), protease inhibitors were from
Roche (Indianapolis, IN, USA), 5-bromo-2′-deoxyuridine
(BrdU) was from Calbiochem (San Diego, CA,
USA), l-[2,3,4,5,6-3H]phenylalanine (3H-Phe) was from
Amersham, and amino acid derivatization reagents
were from Waters (Milford, MA, USA). RNAlater was
obtained from Ambion (Austin, TX, USA), TRIzol
reagent and all oligonucleotides were from Invitrogen
(Carlsbad, CA, USA), RNeasy was from Qiagen
(Valencia, CA, USA), and reverse transcription reagents,
dNTPs and the Primer Express Primer software were
from Applied Biosystems (Foster City, CA, USA).
Bovine anti-goat horseradish-peroxidase-conjugated IgG
was obtained from Santa Cruz Biotechnology (Santa
Cruz, CA, USA), sheep anti-mouse and donkey
anti-rabbit horseradish-peroxidase-conjugated IgG were
from Amersham Pharmacia Biotech (Piscataway, NJ,
USA), enhanced chemiluminescence reagents from
Amersham and Pierce (Rockford, IL, USA), and pre-cast
electrophoresis gels, SDS-PAGE molecular mass markers,
nitrocellulose membranes and protein assay reagent were
from Bio-Rad (Hercules, CA, USA). 4E-BP1 antibody was
obtained from Calbiochem, S6 antibody was from Santa
Cruz, BrdU antibody was from Accurate Chemical and
Scientific Corporation (Westbury, NY, USA), and all other
antibodies were from Cell Signaling (Beverly, MA, USA).
Animal care
Male ICR mice age 6–10 weeks from Harlan (Indianapolis,
IN, USA) weighing approximately 30 g were maintained on
a 12 h light:dark cycle with free access to water and chow
(5001 Rodent Diet; PMI Nutrition International, St Louis,
MO, USA). All animals were killed under carbon dioxide
anaesthesia by decapitation. The University of Michigan
Committee on Use and Care of Animals approved the
animal facilities and the experimental protocol used in
these studies.
Experimental design
In all experiments, animals were acclimated to chow in
powdered form for 3 days prior to further experimental
manipulation. Mice were food deprived overnight for
17 h prior to intraperitoneal injection of either a 2%
CMC solution (1 ml (100 g body weight)−1) or rapamycin
(0.2 mg (100 g body weight)−1) suspended in 2% CMC
solution. One hour following this injection, half of the
animals were provided powdered chow containing 0.1%
camostat. For studies on acute biochemical changes,
mice were killed 2 h later, with food deprivation
continuing for control animals. For chronic growth
studies, animals were injected daily with rapamycin and
killed between 09.00 and 11.00 h after 2–7 days of camostat
feeding, with control animals being fed standard chow.
Preliminary studies demonstrated that a single injection
of rapamycin significantly decreased the phosphorylation
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of both S6 and 4E-BP1 for 24 h (data not shown). In these
experiments, some mice were given an intraperitoneal
injection (1 ml (100 g body weight)−1) of 5 mg ml−1
BrdU solution 1 h prior to tissue collection. Blood was
collected via cardiac puncture under carbon dioxide
anaesthesia, and the pancreas was quickly excised and
weighed. Portions of the pancreas were processed, either
immediately or after freezing in liquid nitrogen, for further
analysis.
Administration of metabolic tracer and measurement
of protein synthesis
Fractional rates of protein synthesis in the pancreas were
determined using the flooding dose method (Garlick et al.
1980) as modified for mice by Lundholm et al. (1991) and
for pancreas by Sans et al. (2003). Briefly, mice were given
an intraperitoneal injection of 3H-Phe (0.4 μCi (g body
weight)−1) and unlabelled l-Phe (1.5 μmol (g body
weight)−1). Ten minutes later, the pancreas was removed
and frozen in liquid nitrogen. A portion of frozen
pancreas was later homogenized in 0.6 M perchloric
acid (1 ml (100 g body weight)−1) and processed as
previously described. l-Phe was measured by HPLC, and
protein synthesis was calculated from the rate of 3H-Phe
incorporation into pancreatic protein using the specific
radioactivity of pancreatic PCA-soluble l-Phe as the
precursor pool.
Quantitative real-time PCR
Total RNA was isolated from pancreatic tissue stored
in RNAlater and isolated using TRIzol and an RNeasy
kit. Total RNA was reverse transcribed and quantitative
real-time PCR was performed using an I-Cycler IQ
real-time PCR detection system with 96-well plates from
Bio-Rad as previously described (Sans et al. 2004a). In
brief, samples were prepared by mixing 10.3 μl HPLC
water, 2 μl 10× PCR buffer, 2.2 μl MgCl2 (50 mm), 1 μl
flourescein, 0.4 μl dNTP (10 mm), 2 μl primer mixtures
containing SYBR Green, and 2 μl cDNA. The primer
sets employed in this study were identical to those
previously described (Guo et al. 2004). Fluorescence
resulting from the incorporation of SYBR Green dye into
the double-stranded DNA produced during PCR was
quantified to obtain the threshold cycle (CT) value for
each sample. The final relative amounts of mRNA were
determined from the CT between experimental and
control groups (Sans et al. 2004a).
Immunoblot analysis
Frozen tissue was homogenized in 2 ml of ice-cold
lysis buffer (pH 7.4) containing (mm): 50 Tris-HCl,
5 ethylenediaminetetraacetic acid, 25 NaF, 10 sodium
pyrophosphate, 50 β-glycerophosphate, 1 phenyl-
methylsulphonyl fluoride, 0.2 Na3VO4, 1 dithiothreitol,
0.2% Triton X-100 (v/v), 5% 2-mercaptoethanol (v/v),
10 μg ml−1 aprotinin, and 10 μg ml−1 leupeptin. The
homogenate was immediately centrifuged at 20 000 g for
15 min at 4◦C. One portion of the resultant supernatant
was used for immunoblot analysis using antibodies that
specifically recognized Akt phosphorylated on Ser473, S6
phosphorylated on Ser240/244, ERKs phosphorylated on
Thr202/Tyr204, p54 JNK phosphorylated on Thr183/Tyr185,
and antibodies that recognized both phosphorylated
and unphosphorylated forms of the respective proteins.
Another portion of the supernatant was prepared
for isoelectric focusing (IEF) gel electrophoresis and
immunoblot analysis with CRHSP-24-specific antiserum
as previously described (Schafer et al. 2003; Tashiro
et al. 2004). An additional portion of the supernatant
was boiled for 15 min and centrifuged at 10 000 g for
30 min at 4◦C. This second supernatant was used for
4E-BP1 immunoblot analyses. Equal amounts of protein
were subjected to SDS-PAGE or IEF gel electrophoresis,
after which the protein was transferred to nitrocellulose
membrane and Western blotting was performed as
previously described (Gautsch et al. 1998). Proteins were
visualized by enhanced chemiluminescence using an
AlphaEase FC8900 imaging system (Alpha Innotech, San
Leandro, CA, USA). Changes in the phosphorylation
state of proteins other than 4E-BP1 were determined by
normalizing the amount of protein in the phosphorylated
form to the total amount of the respective protein prior to
data transformation and are expressed as a percentage of
fasted control values. In cases where the phosphorylation
state of a protein in the fasted condition was too low
for accurate measurement, results were expressed as a
percentage of camostat-fed values. When subjected to
SDS-PAGE, 4E-BP1 resolves into multiple electrophoretic
forms whereby the most highly phosphorylated γ -form
exhibits the slowest mobility, thus allowing for an
assessment of both protein content and phosphorylation
status. Changes in 4E-BP1 phosphorylation were
assessed by calculating the proportion of 4E-BP1 in the
γ -form.
Quantification of pancreatic growth
Following determination of total pancreatic wet weight, a
frozen portion was weighed and homogenized in a solution
(2 ml (100 mg pancreas)−1) containing 0.1% Triton X-100
(v/v) and 5 mm MgCl2, and subsequently sonicated for
15 s. Protein was determined spectrophotometrically using
Bio-Rad protein assay reagent. DNA was assayed using
a DNA Quantification Kit (Sigma-Aldrich) and a Perkin
Elmer LS 55 luminescence spectrometer (Perkin Elmer
Instruments, Norwalk, CT, USA). Total pancreatic protein
and DNA were then calculated.
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Figure 1. Effect of rapamycin on the phosphorylation of Akt
(A), 4E-BP1 (B) and S6 (C), as biomarkers of mTOR pathway
activation
Insets, representative immunoblots. Akt(P), Akt phosphorylated on
Ser473; Akt(T), total Akt content; S6(P), S6 phosphorylated on
Ser240/244; S6(T), total S6 content; α, α form of 4E-BP1; β, β form of
To quantify cellular DNA synthesis, a portion of the
pancreas from mice injected with BrdU was placed in
4% buffered formaldehyde, frozen, and processed for
immunohistochemistry as previously described (Ohnishi
et al. 1996). Sections were exposed to BrdU antibody at
1:50 dilution. Slides were then mounted using prolong
gold antifade reagent containing DAPI (Molecular Probes,
Carlsbad, CA, USA). Digital photographs were obtained of
three separate ×40 fields per pancreas using an Olympus
BX51 fluorescence microscope (Olympus Optical Co.,
Melville, NY, USA). For quantification of acinar cell
nuclei, MetaMorph Offline version 6.1 software (Universal
Imaging Corporation, Downingtown, PA, USA) was used
to count DAPI-stained nuclei of a predetermined size
limit within a field. BrdU-positive acinar cell nuclei within
the same field were counted by hand. The percentage of
BrdU-labelled acinar nuclei was determined by dividing
the number of BrdU-labelled acinar nuclei by the number
of DAPI-stained acinar nuclei within the three fields.
Statistical analysis
Data are expressed as means ± s.e.m. Data were analysed
using the GraphPad Prism statistical software package
(GraphPad Software, Inc., San Diego, CA, USA). Statistical
significance was assessed using a one-way ANOVA and
a Student-Newman-Keuls post test. P values <0.05 were
considered significant.
Results
Rapamycin specifically inhibits stimulation
of the mTOR pathway induced by camostat feeding
Activation of the mTOR signalling pathway is demarcated
by changes in the phosphorylation state of key regulatory
proteins along the pathway. Camostat feeding was
associated with a more than fivefold increase above
fasted control values in the phosphorylation of a kinase
upstream of mTOR, Akt (Fig. 1A). Camostat feeding
was also associated with a 5- and 100-fold increase
above fasted control values in the phosphorylation of
the downstream targets of mTOR, 4E-BP1 (Fig. 1B) and
ribosomal protein S6 (Fig. 1C), respectively. Rapamycin
administration had no effect on the phosphorylation
of Akt, 4E-BP1 or S6 in the pancreas of fasted mice.
Moreover, there was no effect of rapamycin administration
on the increase of Akt phosphorylation in camostat-fed
mice. However, camostat-induced increases in 4E-BP1
4E-BP1; γ , γ form of 4E-BP1. Values represent means ± S.E.M.;
n = 6–8. ∗Significantly different from fasted control value,
†significantly different from camostat-fed value, P < 0.05.
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and S6 phosphorylation were inhibited by 56 and 79%,
respectively, following rapamycin administration.
Rapamycin does not inhibit stimulation
of calcineurin and the MAPK pathways
induced by camostat feeding
It has been demonstrated previously that camostat
feeding not only stimulates the mTOR pathway,
but also calcineurin and the MAPK pathways. To
determine the specificity of rapamycin for the mTOR
pathway following camostat-feeding, changes in
calcineurin activity and MAPK phosphorylation were
assessed. A major target of calcineurin in pancreatic
tissue is the calcium-regulated heat-stable protein
of 24 kDa (CRHSP-24), and dephosphorylation of
CRHSP-24 thereby demarcates increased calcineurin
activity (Groblewski et al. 1998). In the present study,
dephosphorylation of CRHSP-24 was increased following
camostat feeding (Fig. 2A), but was unaffected by
rapamycin administration. Following camostat feeding
there was a nearly 10-fold increase above fasted control
values in the phosphorylation of p44/42 MAPK (ERK)
(Fig. 2B) and p54 JNK (Fig. 2C), indicative of their
activation. Similar to what was observed with changes in
CRHSP-24 phosphorylation, neither the phosphorylation
of JNK nor that of ERK was affected by rapamycin
administration.
Rapamycin does not inhibit early response gene
transcription induced by camostat feeding
An additional hallmark of camostat-induced pancreatic
growth is the induction of early response genes that peaks
at one to two hours postfeeding (Guo et al. 2004). To
evaluate whether rapamycin affected early response gene
expression, quantitative real time PCR was employed to
measure pancreatic mRNA levels of c-jun (Fig. 3A), c-fos
(Fig. 3B), egr-1 (Fig. 3C) and ATF-3 (Fig. 3D). The mRNA
levels of each of these genes was significantly increased
above fasting control levels by 6- to 150-fold in camostat
fed mice, as found previously (Guo et al. 2004), while
there was no change in 18S RNA or GAPDH mRNA
levels (data not shown). These increases in early response
gene mRNA levels were unaffected by treatment with
rapamycin. Rapamycin administration resulted in a small,
but significant, inhibition of fasting c-jun and ATF-3
mRNA levels; however, the significance of this observation
is not clear.
Rapamycin inhibits pancreatic growth induced
by camostat feeding
To address whether selective inhibition of the mTOR
pathway can inhibit pancreatic growth, mice received
Camostat:     – – +      +






























































































Figure 2. Effect of rapamycin on CRHSP-24 (A), p44/p42 MAPK
(B) and p54 JNK (C) phosphorylation
The most highly phosphorylated form of CRHSP-24 (arrow) was
separated from increasingly dephosphorylated forms by isoelectric
focusing and visualized by Western blotting. The amount of
phosphorylated and total ERK was determined from the combined
value of the p44 and p42 bands, while that of phosphorylated and
total JNK was determined from the value of the p54 band only. Insets,
representative immunoblots. p44/p42(P), p44/p42 MAPK
phosphorylated on Thr202/Tyr204; p44/p42(T), total p44/p42 MAPK
content; p54/p56(P), p54/p56 phosphorylated on Thr183/Tyr185;
p54(T), total p54 JNK content. Values represent means ± S.E.M.;
n = 6–8. ∗Significantly different from fasted control value,
†significantly different from camostat-fed value, P < 0.05.
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daily injections of rapamycin while being fed camostat
for 1 week. Similar to that reported previously (Tashiro
et al. 2004), 1 week of camostat feeding did not affect
body weight (data not shown), but resulted in pancreatic
weight increasing from 9.5 ± 0.4 to 24.5 ± 1.8 mg
(g body weight)−1 (Fig. 4A). Neither body weight nor
pancreatic weight was affected following 1 week of
rapamycin injections in mice fed control diet. However,
1 week of daily rapamycin injections almost completely
blocked camostat-induced growth, with pancreatic weight
only increasing to 11.7 ± 0.4 mg (g body weight)−1.
Changes in the size of the pancreas were paralleled by
changes in both DNA (Fig. 4B) and protein (Fig. 4C)
content. DNA content increased from 1.4 ± 0.1 to
3.2 ± 0.03 (mg pancreas)−1 and protein content increased
from 35.0 ± 1.3 to 73.2 ± 6.1 (mg pancreas)−1 and after
7 days of camostat feeding. In contrast, there were no
significant differences in protein or DNA content between
control animals, control diet-fed animals administered
rapamycin, and camostat-fed animals administered
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Figure 3. Effect of rapamycin on early response gene transcription
Relative mRNA levels of c-jun (A), c-fos (B), egr-1 (C) and ATF-3 (D) in pancreas of fasted and camostat-fed
mice administered carboxymethyl cellulose (CMC) or rapamycin as determined by quantitative PCR. Values
represent means ± S.E.M.; n = 5–6. ∗Significantly different from fasted control value, †significantly different from
camostat-fed value, P < 0.05.
rapamycin. Thus rapamycin completely blocked the
increase in pancreatic protein and DNA content in
response to camostat feeding.
Rapamycin inhibits pancreatic DNA synthesis induced
by camostat feeding
The close correlation between increased pancreatic
protein and DNA content observed following 1 week of
camostat feeding in the present study is indicative of
cellular proliferation. To determine whether inhibition
of the mTOR pathway prevents camostat-induced DNA
synthesis, mice were injected with the uridine analogue
BrdU, which is incorporated into newly synthesized DNA
(Fig. 5A). A time course analysis (Fig. 5B) indicated that
DNA synthesis in the pancreas was increased slightly after
1 day of camostat feeding, peaked after 2 days, and then
declined but remained elevated after 5 days of camostat
feeding. Therefore, the effect of rapamycin was studied in
mice after 2 days of camostat feeding and daily rapamycin
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injections. Camostat feeding for 2 days resulted in a 45-fold
increase in BrdU incorporation (Fig. 5A and C) above
control levels. Rapamycin had no effect on incorporation
in mice fed control diet, but inhibited camostat-induced
BrdU incorporation by more than 98%.
Rapamycin inhibits stimulation of global protein
synthetic rates induced by camostat feeding
Previous studies in our laboratory have shown that
pancreatic weight and protein increase in parallel
after camostat feeding. These increases necessitate an
increase in pancreatic protein synthetic rates and/or
an inhibition of digestive enzyme secretion. The latter
possibility seems unlikely, however, as CCK is a
well-established pancreatic secretagogue and rapamycin
does not block amylase secretion in vitro (Bragado
et al. 1998). We therefore measured pancreatic protein
synthesis (Fig. 6) 2 h after the initiation of camostat
feeding and found that global rates were increased from
2.75 ± 0.35 nmol Phe (mg protein)−1 (10 min)−1 in fasted
mice to 3.76 ± 0.35 nmol Phe (mg protein)−1 (10 min)−1
in camostat fed animals. Rapamycin administration had
no effect on synthesis rates in fasted mice; however, it
completely prevented the camostat-induced stimulation
of pancreatic protein synthesis.
Discussion
The present study documents that activation of the mTOR
pathway is required for camostat-induced pancreatic
growth. Administration of the mTOR inhibitor rapamycin
did not affect camostat-induced calcineurin and MAPK
activation or early response gene transcription. Moreover,
previous studies have demonstrated that rapamycin
does not affect CCK-induced amylase secretion in
isolated pancreatic acini (Bragado et al. 1998). However,
rapamycin administration significantly attenuated the
increased phosphorylation of 4E-BP1 and ribosomal
protein S6, as well as the increased rates of pancreatic
protein synthesis, observed acutely following camostat
feeding. Daily rapamycin administration also abolished
the increases in pancreatic DNA synthesis and growth
observed following prolonged camostat feeding.
Activation of the serine/threonine-specific protein
phosphatase calcineurin was previously identified as a
necessary step in the induction of pancreatic growth
following camostat feeding (Tashiro et al. 2004). It was not
known, however, whether activation of calcineurin by itself
was sufficient to cause pancreatic growth. The results from
this study demonstrating that rapamycin administration
inhibited pancreatic growth, but not calcineurin-mediated
dephosphorylation of CRHSP-24, make it likely that
camostat-feeding-induced activation of calcineurin alone
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Figure 4. Effect of rapamycin on pancreatic growth in mice fed
camostat for 7 days
Pancreatic weight (A), DNA content (B) and protein content (C) of
mice given daily injections of CMC or rapamycin and fed standard
chow or camostat-enriched chow for 7 days. Values represent
means ± S.E.M.; n = 6–7. ∗Significantly different from fasted control
value, †significantly different from camostat-fed value, P < 0.05.
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is not sufficient to induce pancreatic growth. A possible
caveat to this conclusion, however, is that mTOR may
be regulated by calcineurin following camostat feeding.
In a recent study involving isolated pancreatic acinar
cells, administration of the calcineurin inhibitor FK506
resulted in the dephosphorylation of 4E-BP1, but not
S6 (Sans & Williams, 2004). In a more recent in vivo
study, FK506 decreased, but did not completely inhibit
camostat feeding-induced phosphorylation of both
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Figure 5. Effect of rapamycin on pancreatic DNA synthesis
A, immunostaining of BrdU in pancreatic acinar cell nuclei. B, time course of BrdU incorporation in the pancreas
of camostat-fed mice. C, BrdU incorporation in pancreas of mice given daily injections of CMC or rapamycin and
fed standard chow or camostat-enriched chow for 2 days. Values represent means ± S.E.M.; n = 9. ∗Significantly
different from fasted control value, †significantly different from camostat-fed value, P < 0.05.
4E-BP1 and S6 (Tashiro et al. 2006). Calcineurin activity
may thus affect 4E-BP1 and S6 phosphorylation through a
hitherto unknown mTOR-dependent pathway. However,
the present results clearly demonstrate that inhibition
of the mTOR pathway inhibits growth independent
of calcineurin following camostat feeding. Therefore,
activation of both calcineurin and the mTOR pathway
appear to be necessary for camostat-induced pancreatic
growth.
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Activation of the mTOR pathway is associated with
increased translation of mRNAs containing a 5′-terminal
oligopyrimidine sequence and mRNAs with highly
structured 3′ untranslated regions in particular (Meyuhas,
2000; Khan & Goss, 2005). The aforementioned mRNAs
encode many proteins required for cell growth, such
as ribosomal proteins and translation factors (Meyuhas,
2000; Kimball & Jefferson, 2004). mTOR also modulates
cell growth via phosphorylation of the nucleolar
transcription factor UBF which stimulates ribosomal DNA
transcription (Hannan et al. 2003). Recently, it has been
demonstrated that mTOR activity also affects various cell
cycle regulators. For example, rapamycin administration
inhibits serum-stimulated increases in cyclin D1 protein
and the resultant induction of CDK-4 kinase activity
(Nader et al. 2005). Induction of CDK-4 kinase activity
is required for entry of a cell into the G1 phase of the cell
cycle, and, in the present study, rapamycin administration
inhibited camostat feeding-induced increases in BrdU
incorporation, indicating that camostat-induced cell cycle
entry was indeed blocked.
The changes in MAPK activation observed in the
current study are likely to have an impact upon changes
in the pancreatic proteome following camostat feeding.
The MAPKs are important regulators of transcription,
including that of the early response genes (Minet
et al. 2001). Therefore, the camostat feeding-induced
changes in early response gene expression observed both
previously (Guo et al. 2004) and in the present study
are likely to be mediated, at least in part, by ERK
and JNK. As the early response genes encode factors
that regulate the proliferation of many cell types,
ERK and JNK activation is likely to be important in
the regulation of pancreatic growth. Neither camostat
feeding-induced ERK and JNK phosphorylation, nor
activation of the early response genes, were affected by
rapamycin administration in the present study and these
changes thus appear to be independent of the mTOR
pathway. In a recent paper (Tashiro et al. 2006), it
was demonstrated that administration of the calcineurin
inhibitor FK506 blocks camostat feeding-induced JNK,
but not ERK, phosphorylation. Thus, while JNK activation
may be mediated by calcineurin in vivo, ERK activation
appears to be independent of both mTOR and calcineurin
and it will be important for future studies to address
whether activation of the MAPKs is necessary or sufficient
for pancreatic growth following camostat feeding or
whether activation of calcineurin, mTOR and the
MAPKs are all necessary for camostat-induced pancreatic
growth.
Interestingly, the rates of pancreatic protein synthesis
observed 2 h following the initiation of consumption of
camostat-containing chow in the current study are no
greater than those observed 2 h following the initiation of
consumption of standard chow in a prior study (Sans et al.
2004a). Increased rates of protein synthesis are required
for pancreatic growth, but as feeding standard chow is
not associated with pancreatic growth in mice, there
must be an underlying difference between the changes
in protein synthesis initiated by feeding chow containing
camostat and those initiated by feeding standard chow.
One possible difference between these two diets is the
duration for which they stimulate pancreatic protein
synthetic rates. Pancreatic protein synthesis rates have
been shown to be greater than fasting levels in mice
allowed access to food for 1 or 2 h, but not 3 h,
following 18 h of food deprivation (Sans et al. 2004a).
In contrast, the stimulation of protein synthesis following
consumption of a camostat-containing meal appears to
be far more prolonged. We recently determined that after
2 days of camostat feeding, pancreatic protein synthetic
rates are 32% greater per milligram of protein than
for mice freely fed standard chow (unpublished data).
These results are in keeping with prior observations that
the duration, but not the magnitude, of CCK release
is greater in rats fed soybean trypsin inhibitor than
in those fed casein (Liddle et al. 1986). Thus, it may
be that the stimulation of protein synthesis observed
following normal feeding is sufficient to maintain cell
size, while the prolonged stimulation observed following
camostat feeding is necessary for cell division. An
additional, and not mutually exclusive, explanation for the
differences in pancreatic growth following standard chow
feeding and feeding chow supplemented with camostat
is variations in the synthesis of specific proteins. For
example, given the camostat feeding-specific activation
of MAPKs and the known transcriptional effects of the
MAPKs, it is highly plausible that there are significant
differences in the mRNAs available for translation between
camostat-fed and standard chow-fed animals. Finally, it
Camostat:     – – +       +























Figure 6. Effect of rapamycin on pancreatic protein synthesis
Rates of global pancreatic protein synthesis in fasted and 2 h
camostat-fed mice administered CMC or rapamycin as assessed by the
incorporation of 3H-Phe into pancreatic protein during a 10 min
period. Values represent means ± S.E.M.; n = 5–6. ∗Significantly
different from fasted control value, †significantly different from
camostat-fed value, P < 0.05.
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has been estimated that 90% of protein synthesis in the
pancreas can be attributed to digestive enzymes (Scheele,
1993). Therefore, it is unlikely that the synthesis of
proteins required for camostat-induced cell growth and
proliferation would result in measurable changes in global
protein synthetic rates, as measured by the flooding dose
method, until after additional synthetic machinery had
been synthesized and acinar cells were entering mitosis. As
protein synthesis measurements in the present study were
made 2 h after feeding, it is likely that the bulk of protein
synthesis was directed towards digestive enzyme synthesis
and not cell growth. Therefore, it is highly possible that
the pancreatic proteome of camostat fed mice differs
significantly from that of a standard chow fed mice 2 h after
the initiation of feeding despite there being no difference
in their protein synthetic rates.
While the effects of camostat feeding on pancreatic
growth in this study have been primarily attributed to
CCK, the gastrointestinal hormone secretin may also be
playing an important role. Camostat feeding results in
significant increases in circulating secretin (Watanabe et al.
1992). Moreover, it has been demonstrated that both CCK
and secretin are required for maximal camostat-induced
digestive enzyme secretion (Watanabe et al. 1992). While
secretin alone has minimal effects on pancreatic growth,
secretin enhances growth of the pancreas in response to
administration of the CCK analogue caerulein (Solomon
et al. 1978). Thus, the effects of camostat on pancreatic
growth may be mediated by the combination of CCK
and secretin. Activation of the mTOR pathway however, is
unlikely to be modulated by secretin. The effects of secretin
on intracellular signalling are mediated by adenylate
cyclase and, unlike CCK, adenylate cyclase agonists and
cAMP analogues do not effect the phosphorylation of
downstream targets of mTOR in isolated acini (Bragado
et al. 1997; Sans et al. 2004b).
In conclusion, the results presented herein demonstrate
that the mTOR signalling pathway is necessary for
pancreatic cell division and growth following camostat
feeding. Moreover, the results demonstrate that the mTOR
pathway plays a critical role in the regulation of both
pancreatic protein and DNA synthesis in this model.
Thus, mTOR joins calcineurin as an essential modulator
of pancreatic growth in protease inhibitor-treated mice.
These findings demonstrate that multiple signalling
pathways are required to initiate pancreatic growth and
an important avenue for future research will be to identify
the other signalling pathways that are necessary for this
process.
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